ライフサイエンスコーパス: alkylating

1 ere treated with RT, and almost 40% received alkylating agent (AA) -containing chemotherapy (predomin

2 Cumulative exposure to alkylating agent (AA) was notably lower in the G studies

3 erapy with bortezomib, dexamethasone, and an alkylating agent (BDex+AA) is associated with improved b

4 r rad50 after exposure to UV-C radiation, an alkylating agent (N-methyl-N'-nitro-N-nitrosoguanidine),

5 rgeting of KRAS mutant DNA using a synthetic alkylating agent (pyrrole-imidazole polyamide indole-sec

6 from the corresponding N-alkyl imidazole, an alkylating agent (usually MeI), and sodium borohydride (

7 yes/no), radiation to the neck (yes/no), and alkylating agent (yes/no).

8 abine), 4-6 of 6 matched dUCB-other (n = 40; alkylating agent + fludarabine +/- TBI), and 8 of 8 (n =

9 Compared with temozolomide, a clinical DNA-alkylating agent against glioma, 6OTD required lower con

10 at G4 targeting of this clinically important alkylating agent alters the overall mechanism of action.

11 Conditioning regimens consisted of an alkylating agent and fludarabine, and GVHD prophylaxis i

12 rate that ALX, through its dual action as an alkylating agent and topoisomerase inhibitor, represents

13 Treatment of animals with the alkylating agent azoxymethane resulted in both liver tox

14 TH-302, a prodrug of the cytotoxic alkylating agent bromo-isophosphoramide mustard, is pref

15 more than 50% decrease in the LD(50) for DNA-alkylating agent carmustine (BCNU), which is commonly us

16 10.5-41.6] since diagnosis) who had received alkylating agent chemotherapy but no radiation therapy.

17 Increasing doses of uterine radiation and alkylating agent chemotherapy were strongly associated w

18 ing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities

19 Given the activity of the lenalidomide-alkylating agent combination in myeloma, we designed thi

20 ients with prior exposure to fludarabine and alkylating agent combinations, and patients with prior e

21 eath induced by cyclophosphamide (CP), a DNA alkylating agent commonly used in chemotherapy.

22 increase in mutations and sensitivity to an alkylating agent compared with the WT hMPG.

23 We report that the combined use of the alkylating agent cyclophosphamide (CTX) and an agonist a

24 Those with a summed alkylating agent dose (AAD) score of three or four or wh

25 2; 95% CI, -0.02 to 0.64), higher cumulative alkylating agent dose (AAD) score or treatment with cycl

26 ed with pelvic irradiation and/or increasing alkylating agent doses were at risk for acute ovarian fa

27 Direct normoxic PARP1 activation by a DNA alkylating agent enhanced Bnip3 expression, and caused B

28 ta define the dose-specific relation between alkylating agent exposure and semen variables in adult s

29 Alkylating agent exposure was associated with an 8.8-fol

30 Alkylating agent exposure was estimated using the cyclop

31 nt stem cell collection prior to significant alkylating agent exposure, given its potential deleterio

32 under basic conditions in the presence of an alkylating agent leads to atropselective O-alkylation wi

33 Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade gl

34 replication slowing; upon treatment with the alkylating agent methyl methane sulfonate, cds1Delta mut

35 ar protein reorganization on exposure to the alkylating agent methyl methanesulfonate (MMS).

36 leotide resolution in yeast treated with the alkylating agent methyl methanesulfonate (MMS).

37 e products that modulate the toxicity of the alkylating agent methyl methanesulfonate (MMS).

38 e was enhanced upon DNA damage caused by the alkylating agent methyl methanesulfonate and that the re

39 arly severe in mutant cells treated with the alkylating agent methyl methanesulfonate.

40 Administration of the DNA-alkylating agent methylazoxymethanol acetate (MAM) on em

41 ystem, leads to increased sensitivity to the alkylating agent MMS and hyper-recombination in an oligo

42 312 helps to prevent tumour induction by the alkylating agent MNU, which predominantly caused T cell

43 The trichloroacetimidate alkylating agent must be a stable cation precursor for t

44 h UV radiation and a minimal dose of the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine.

45 o had not had a response to rituximab and an alkylating agent or had had a relapse within 6 months af

46 All patients received alkylating agent plus fludarabine; 792 received allograf

47 oses of radiation to the ovaries, increasing alkylating agent score, and a diagnosis of Hodgkin's lym

48 etic diseases, the use of MTX rather than an alkylating agent such as cyclophosphamide would be prefe

49 ER and enhancing the cytotoxic effect of DNA-alkylating agent Temozolomide (TMZ) in mismatch repair (

50 tant radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ).

51 udes radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ).

52 tic response came from use of the S(N)1-type alkylating agent temozolomide in combination with ionizi

53 evealed that LCA exhibits synergism with the alkylating agent temozolomide, which engages BER through

54 s glioblastoma-resistant cancer cells to the alkylating agent temozolomide.

55 y the proteasome inhibitor bortezomib or the alkylating agent temozolomide.

56 increased invasiveness and resistance to the alkylating agent temozolomide.

57 ; tetrachlorobenzoquinone (TCBQ) is a potent alkylating agent that reacts with cellular thiols at a d

58 es with increased therapeutic sensitivity to alkylating agent therapy.

59 of the cobalt complex with 0.75 mol % of the alkylating agent to afford the desired products in up to

60 A and R69F mutants are more sensitive toward alkylating agent toxicity, revealing the key role of Arg

61 lthough the gene transcription is induced by alkylating agent treatment, the protein is degraded in v

62 Temozolomide (TMZ) is an oral alkylating agent used for the treatment of high-grade gl

63 od was applied to temozolomide, an important alkylating agent used in the treatment of brain tumors,

64 Temozolomide is a DNA-alkylating agent used to treat brain tumors, but resista

65 A adducts based on the reactivity of the DNA alkylating agent was demonstrated by inclusion of an ion

66 An isoxazole-based alkylating agent was developed to selectively alkylate c

67 Cyclophosphamide (CPA) is a DNA alkylating agent widely used in cancer chemotherapy.

68 le mice with melphalan (MLP), a bifunctional alkylating agent widely used in chemotherapy, induces DN

69 Bendamustine hydrochloride is an alkylating agent with novel mechanisms of action.

70 g with two alkylating agents (p=0.015 vs one alkylating agent) and last available pre-HSCT bilirubin

71 to monensin but also to salinomycin and the alkylating agent, methylnitrosourea.

72 ly accelerated by treatment of mice with the alkylating agent, N-ethyl-N-nitrosourea (ENU), regardles

73 d after reduction of receptor reserve by the alkylating agent, phenoxybenzamine, as it reduced the ma

74 ent of polymers with methyl iodide (MeI), an alkylating agent, to convert polymer-bound tertiary amin

75 laromustine (VNP40101M), a sulfonylhydrazine alkylating agent, was conducted in patients age 60 years

76 confirm the formation of PARP-1 DPCs during alkylating agent-induced base excision repair (BER) and

77 ine is a newly approved and better-tolerated alkylating agent.

78 N-ethylmaleimide (NEM), a cysteine-selective alkylating agent.

79 lex was more resistant to inactivation by an alkylating agent.

80 e in vitro and confers protection from a DNA-alkylating agent.

81 ivalent requiring metabolic breakdown to the alkylating agent.

82 verse nucleophiles using methylarenes as the alkylating agent.

83 , an imidazotetrazine-class chemotherapeutic alkylating agent.

84 yl trifluoromethanesulfonate as a reversible alkylating agent.

85 icrotubule toxin and a duocarmycin-class DNA-alkylating agent.

86 s as a topoisomerase inhibitor as well as an alkylating agent.

87 ng bromocrotonate as the activated methylene alkylating agent.

88 The use of an alkene as the formal "alkylating" agent associated with the tolerance for nume

89 al tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT.

90 %) or in association with rituximab (21.1%), alkylating agents (36.8%) or a combination of cyclophosp

91 patients), purine analogs (26 patients), or alkylating agents (39 patients).

92 ies), including proteasome inhibitors (91%), alkylating agents (91%), autologous stem cell transplant

93 , we quantified cumulative doses of specific alkylating agents (AAs) and reconstructed radiation dose

94 anthracycline (HR, 2.6; 95% CI, 1.6-4.3) or alkylating agents (HR, 1.7; 95% CI, 1.2-2.5), non-breast

95 Cellular sensitivity to two monofunctional alkylating agents (methyl methane sulfonate and N-methyl

96 multivariate analysis, conditioning with two alkylating agents (p=0.015 vs one alkylating agent) and

97 elative risk [RR], 2.9; 95% CI, 2.1 to 4.2), alkylating agents (RR, 2.2; 95% CI, 1.6 to 3.0), and epi

98 Exposure of Escherichia coli to alkylating agents activates expression of AidB in additi

99 Treatment with alkylating agents also was not significantly associated

100 adiation and treatment with a combination of alkylating agents and anthracyclines.

101 otoxic agent with structural similarities to alkylating agents and antimetabolites, but which is non-

102 onse resulting from DNA crosslinking agents, alkylating agents and camptothecin.

103 esponse to replicative stress induced by DNA alkylating agents and greatly influences drug response i

104 duced by lysosomal injury resulting from DNA alkylating agents and hypotonic shock, whereas it promot

105 ive SCID suggest that minimizing exposure to alkylating agents and ionizing radiation is important fo

106 ne (1-MeA) is formed in DNA by reaction with alkylating agents and naturally occurring methyl halides

107 lites, but which is non-cross-resistant with alkylating agents and other drugs in vitro and in the cl

108 high-dose radiation (especially over 10 Gy), alkylating agents and procarbazine, at older ages, were

109 survival following first-line treatment with alkylating agents and purine analogs.

110 ated with defective apoptosis in response to alkylating agents and purine analogues.

111 plausible cause-effect relationship between alkylating agents and PVOD.

112 ne questionnaire, and quantified exposure to alkylating agents and radiation therapy.

113 We quantified chemotherapy with alkylating agents and radiotherapy doses to the testes a

114 ses and related quaternary ammonium salts as alkylating agents and singlet oxygen sensitizers.

115 compromise fertility, especially exposure to alkylating agents and whole body irradiation, which caus

116 ng adult (CAYA) cancer who were treated with alkylating agents and/or radiation, with potential expos

117 s in Diels-Alder reactions and electrophilic alkylating agents are described.

118 The mutagenic and cytotoxic effects of many alkylating agents are reduced by O(6)-alkylguanine-DNA a

119 Dose escalation of alkylating agents as tested in this trial did not improv

120 N) or CB-839, hypersensitize cancer cells to alkylating agents both in vitro and in vivo.

121 poxic microenvironment induces resistance to alkylating agents by activating targets in the mammalian

122 Alkylating agents can induce sustained drug-free remissi

123 ored by depletion of Top1, illustrating that alkylating agents can trigger cytotoxic Top1-breaks.

124 one alone (control group) concomitantly with alkylating agents containing chemotherapy.

125 Trichloroacetimidates are useful alkylating agents for aromatic amines, requiring only a

126 of maximizing the chemotherapeutic value of alkylating agents for cancer treatment.

127 nd their relationship to genotype and use of alkylating agents for conditioning.

128 thiol derivatives with Michael acceptors and alkylating agents furnished thioglycosides and (1,1)-thi

129 s underlying the sensitivity of IDE to thiol-alkylating agents has not been elucidated.

130 that might predict a better response to DNA alkylating agents have been identified in GBMs, except f

131 pated and unknown DNA adducts induced by DNA alkylating agents in biological samples.

132 icancer cotherapies, used as enhancements of alkylating agents in chemotherapy.

133 erase (MGMT), a key enzyme for resistance to alkylating agents in glioblastoma patients.

134 Due to the abundant presence of alkylating agents in living cells and the environment, D

135 ht alcohols such as ethanol could be used as alkylating agents in this methodology.

136 Alkylating agents induce cytotoxic DNA base adducts.

137 In wild-type animals DNA alkylating agents induce photoreceptor apoptosis and sev

138 reviously shown in tumor xenografts that DNA alkylating agents induce sporadic cell necrosis and regr

139 However, use of preconditioning with alkylating agents is associated with a greater likelihoo

140 The benefit of cancer chemotherapy based on alkylating agents is limited because of the action of DN

141 DNA alkylating agents like nitrogen mustard (NM) are easily

142 ssays and potentiate the cytotoxicity of the alkylating agents methylmethane sulfonate and temozolomi

143 F can be developed to enhance the effects of alkylating agents on cancer cells.

144 cing intracellular NAD(+) depletion, such as alkylating agents or direct NAD(+) synthesis inhibitors,

145 phocytic leukemia (CLL) who are treated with alkylating agents or single-agent fludarabine, its signi

146 itivity was not observed upon treatment with alkylating agents or UV irradiation.

147 cacy compared with corticosteroids alone and alkylating agents plus corticosteroids to achieve comple

148 Although cytotoxic alkylating agents possessing two electrophilic reactive

149 with 100% sperm retrieval while exposure to alkylating agents resulted in a significantly lower sper

150 Alkylating agents such as temozolomide lose their effica

151 y especially benefit from treatment with DNA alkylating agents such as temozolomide.

152 tion damage by protecting DNA and destroying alkylating agents that have yet to reach their DNA targe

153 n the presence of sodium dodecyl sulfate and alkylating agents that irreversibly inhibit Ubl protease

154 Both classes of compound are potent alkylating agents that may need to be considered in futu

155 ic fibroblasts are specifically sensitive to alkylating agents that result in O6-methylguanine adduct

156 Oxazaphosphorines are alkylating agents used in routine clinical practices for

157 n whose mothers were exposed to radiation or alkylating agents versus neither, the prevalence of anom

158 eloped a strategy to harness alkyl amines as alkylating agents via C-N bond activation.

159 on, corticosteroids, and chronic exposure to alkylating agents via distinct molecular routes involvin

160 Exposure to alkylating agents was observed in 83.8% of cases, mostly

161 4-(p-nitrobenzyl)pyridine (NBP), a trap for alkylating agents with nucleophilic characteristics simi

162 re susceptible to bi- and tri-functional DNA alkylating agents with this phenotype readily complement

163 no optimal approach that uses standard dose-alkylating agents without significant late effects.

164 st the hypothesis that increased exposure to alkylating agents would be associated with decreased spe

165 s, a mild protocol using simple and abundant alkylating agents would have considerable use in the syn

166 an catalyze the hydrolysis of the potent DNA-alkylating agents yatakemycin (YTM) and CC-1065.

167 EN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and

168 s-resistant drugs used for conditioning (eg, alkylating agents) could favor elimination of residual c

169 tients, is associated with prior exposure to alkylating agents, and a high frequency of TP53 loss or

170 istant to conventional (e.g., dexamethasone, alkylating agents, and anthracyclines) or novel (e.g., t

171 r-stable and inexpensive nitroalkanes as the alkylating agents, and delivers synthetically versatile

172 MGMT) in tumor correlates with resistance to alkylating agents, and depletion of MGMT activity can en

173 op1 inhibitors, but also to Top2 inhibitors, alkylating agents, and DNA synthesis inhibitors.

174 trobenzofurazan-based scaffolds, maleimides, alkylating agents, and electrophilic aldehydes, toward c

175 such as exposure to reactive oxygen species, alkylating agents, and many of the antibiotics targeting

176 intestinal cancer associated with exogenous alkylating agents, and that endogenous alkylation does n

177 repair kinetics and increases sensitivity to alkylating agents, but not other forms of DNA damage.

178 Nitrosoureas, traditionally viewed as DNA alkylating agents, can also covalently modify proteins s

179 ed necrotic cell death, induced by cytotoxic alkylating agents, hyperactivation of poly-ADP-ribose po

180 severe lesions that can be produced by many alkylating agents, including N-methyl-N'-nitro-N-nitroso

181 sm may not augment some regionally delivered alkylating agents, leading to a net increase in tumor si

182 reatment following topoisomerase II poisons, alkylating agents, local radiation, hematopoietic stem c

183 Using thiol-alkylating agents, mass spectrometry, and an assay for a

184 tive lesions, upon exposure to UV radiation, alkylating agents, or oxidative conditions.

185 a (WM) and closely related disorders include alkylating agents, purine analogs, and monoclonal antibo

186 agents in WM include monoclonal antibodies, alkylating agents, purine analogs, proteasome inhibitors

187 Treatment with alkylating agents, second-line therapy, and age older th

188 Alkylating agents, such as cyclophosphamide, set up the

189 changes color upon the exposure to dangerous alkylating agents, such as iodomethane vapor, without th

190 of bases damaged by oxidative metabolism or alkylating agents, such as those commonly used in cancer

191 proaches with alkyl halides or sulfonates as alkylating agents, the use of unactivated olefins for al

192 ch relies on the synthesis of (13)C-enriched alkylating agents, was applied to the production of 15-r

193 oma cells to apoptosis following exposure to alkylating agents, while not affecting primary melanocyt

194 ylation strategy using simple olefins as the alkylating agents.

195 ersus-host disease regardless of exposure to alkylating agents.

196 poor growth in ARTEMIS deficiency and use of alkylating agents.

197 m to repair DNA adducts and are sensitive to alkylating agents.

198 e metabolism to form potent DNA minor groove-alkylating agents.

199 otizing scleritis may respond to IMT, mainly alkylating agents.

200 2-diketones using simple terminal olefins as alkylating agents.

201 reactive methyl donor, and by reaction with alkylating agents.

202 ses, these compounds convert into active DNA-alkylating agents.

203 ge may protect the active site cysteine from alkylating agents.

204 es, which include ionizing radiation and DNA-alkylating agents.

205 ed upon exposure to endogenous and exogenous alkylating agents.

206 unity and tumor clearance in response to DNA alkylating agents.

207 tion with dexamethasone, anthracyclines, and alkylating agents.

208 ation of ketones using simple alkenes as the alkylating agents.

209 s an important role by protecting cells from alkylating agents.

210 foci specifically upon exposure of cells to alkylating agents.

211 esistance to certain cancer chemotherapeutic alkylating agents.

212 phenylalanine) and involve Me2Zn or Et2Zn as alkylating agents.

213 nse of malignant melanoma cells treated with alkylating agents.

214 ator compound for many types of carcinogenic alkylating agents.

215 and can detect both gas- and solution-phase alkylating agents.

216 t severe, pulmonary vascular complication of alkylating agents.

217 s makes them significantly more sensitive to alkylating agents.

218 SCC foci formation and are hypersensitive to alkylating agents.

219 nd intrastrand cross-linking agents, but not alkylating agents.

220 h antimetabolites, T-cell inhibitors, and/or alkylating agents.

221 protects cells from carcinogenic effects of alkylating agents; however, MGMT is silenced by promoter

222 linked with increased susceptibility to DNA alkylating and inter-strand cross-linking agents.

223 on but show reduced viability in the face of alkylating and oxidative damage, increased mtDNA degrada

224 sses necrotic cell death induced by numerous alkylating and oxidizing agents while having no effect o

225 We extracted doses of 14 alkylating and similar DNA interstrand crosslinking drug

226 Maleimide-based, alkylating, and aldehydic thiol labeling reagents provid

227 d iNKT cells were pretreated with the A(2A)R alkylating antagonist, FSPTP (5-amino-7-[2-(4-fluorosulf

228 reported correlation between sensitivity to alkylating anticancer agents and topoisomerase inhibitor

229 be superior in the colorimetric assay of the alkylating anticancer drug cyclophosphamide.

230 e affords ethanesultone (ES), which displays alkylating capacity on the nucleophile 4-(p-nitrobenzyl)

231 ratinocytes upon exposure to UVB and the DNA-alkylating chemicals such as methyl methanesulphonate (M

232 Genotoxic agents such as UV and alkylating chemicals trigger a DNA damage response in wh

233 lethal doses of carmustine (BCNU), a classic alkylating chemotherapeutic agent used in treatment of g

234 '-nitro-nitrosoguanidine (MNNG, a common DNA-alkylating chemotherapeutic agent).

235 ntributes to the resistance of tumors to DNA-alkylating chemotherapeutic agents.

236 that clinically relevant dosages of standard alkylating chemotherapies, such as temozolomide and cycl

237 ey show that in ARTEMIS patients, the use of alkylating chemotherapy agents is associated with a high

238 Dose-response relationships for alkylating chemotherapy and age at treatment are both li

239 otherapy and dose-response relationships for alkylating chemotherapy and age at treatment.

240 Dose relationship between alkylating chemotherapy and POF occurrence was linear.

241 In women treated without alkylating chemotherapy at age younger than 32 years and

242 Resistance toward alkylating chemotherapy but not radiotherapy was depende

243 ssue was not more predictive for response to alkylating chemotherapy in patients who received concomi

244 Alkylating chemotherapy or pelvic radiotherapy diminishe

245 Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and

246 erapy for malignancies that are treated with alkylating chemotherapy, and the contribution of standar

247 1) as a key determinant of resistance toward alkylating chemotherapy, driven by hypoxia but also by t

248 als are often conducted after treatment with alkylating chemotherapy, given either as standard therap

249 s induced and predictive of poor response to alkylating chemotherapy.

250 d to avoid exposing responder lymphocytes to alkylating chemotherapy.

251 t macaques that were rendered infertile with alkylating chemotherapy.

252 Alkylating commercial 2-pyridinesulfonylacetonitrile wit

253 Nitrogen mustards (NMs) are DNA-alkylating compounds that represent the earliest antican

254 ntage of increased residence time at EGFR by alkylating Cys797 and thereby preventing toxic effects.

255 To model endogenous alkylating damage, we determined the mutation spectrum c

256 egradation in response to both oxidative and alkylating damage.

257 milar episulfonium ion intermediate, thereby alkylating DNA and leading to eventual cell death.

258 Mechanistically, upon oxidative stress or alkylating DNA damage, PARP1 interacts with and attaches

259 rast, inhibition of PARP by PARPi attenuates alkylating DNA damage-induced EZH2 downregulation, there

260 an episulfonium ion intermediate capable of alkylating DNA.

261 18 times more sensitive to Bizelesin, a DNA alkylating drug compared to WT parasites as reflected by

262 Gy [13.0] for women), and chemotherapy with alkylating drugs (26 [2%] of 1195 women, 0.9 [0.5-1.5];

263 Greater doses of contemporary alkylating drugs and cisplatin were associated with a de

264 g Rnf4 are hypersensitive to hyroxyurea, DNA alkylating drugs and DNA crosslinking agents, but this s

265 ression and restores chemosensitivity of DNA-alkylating drugs in mouse models.

266 ease in children and parental treatment with alkylating drugs or preconception radiation doses to the

267 melanoma therapy with temozolomide and other alkylating drugs suggests a combination approach where c

268 contribute to resistance of melanomas to the alkylating drugs temozolomide, dacarbazine, and fotemust

269 gammaglobulinemia, conventional therapy with alkylating drugs, and recently, purine analogs and mAb-a

270 ajor role in MMR-dependent cell death by DNA alkylating drugs.

271 d with the sensitivity toward venetoclax and alkylating drugs.

272 Thus, these specialized alkylating enzymes have dramatic and fully opposed effec

273 at alternatives, such as cyclophosphamide or alkylating-free combinations, should be considered inste

274 yl bond of TrapG generates a highly reactive alkylating group that facilitates the attachment of the

275 tives characterized by variously substituted alkylating groups on the nitrogen atom of the quinolinon

276 ation of carbon-centered radicals capable of alkylating heme and/or protein.

277 ameliorating the efficacy of the most common alkylating immunomodulatory compound.

278 lar modeling studies with both mono- and bis-alkylating ligands indicated that the ligands fit tightl

279 adducts in DNA that are generated by various alkylating mutagens and drugs.

280 lls treated with PR104A, an experimental DNA alkylating nitrogen mustard prodrug currently under inve

281 sistance to UV, ionizing radiation, chemical alkylating or cross-linking agents.

282 nonepimerizing chemo- and enantioselective N-alkylating procedure has been developed via oxidation/im

283 Addition of two equivalents of an alkylating reagent to UO2 X2 (L)2 (X=Cl, Br, I, OTf; L=t

284 The alkylating reagent, N-(phenylseleno)phthalimide (NPSP),

285 rs using alcohols for in situ preparation of alkylating reagents is reported.

286 s polymerization (ROMP) for use as efficient alkylating reagents is reported.

287 suggests a kinetic anionic activation of the alkylating reagents occurs, favoring nucleophilic additi

288 icable use of unactivated alcohols as latent alkylating reagents, achieved via the successful merger

289 ntal lineCH(t)Bu(OTf)] and the corresponding alkylating reagents, LiCH2CHR (R = H, CH3(unstable), CH2

290 Using physicochemically different alkylating reagents, sites predominantly lining the cyto

291 ass, such as lignocellulose, are employed as alkylating reagents.

292 y available uranyl salts, silyl halides, and alkylating reagents.

293 strategy for replacing toxic, electrophilic alkylating reagents.

294 tion of heteroarenes, using alcohols as mild alkylating reagents.

295 pecific quantitative approach integrating an alkylating resin-assisted capture and mass spectrometry-

296 alogues might be exploited to activate a DNA-alkylating species selectively in hypoxic tissue.

297 dification is removed through catalysis; and alkylating the cysteine blocks activity.

298 are responsible for the effectiveness of DNA-alkylating therapies.

299 In this study, we show that whereas DNA alkylating therapy leads to a complete tumor regression

300 kine array analysis reveals that whereas DNA alkylating treatment leads to suppression of protumor cy